Potential Medications for the Treatment of Alcohol use Disorder: An Evaluation of Clinical Efficacy and Safety
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Alcohol use disorder (AUD), as currently defined in the Diagnostic and Statistical Manual, 5th Edition (DSM–5), is a heterogeneous disorder stemming from a complex interaction of neurobiological, genetic, and environmental factors. As a result of this heterogeneity, there is no one treatment for AUD that will work for everyone. During the past 2 decades, efforts have been made to develop a menu of medications to give patients and clinicians more choices when seeking a therapy that is both effective and which has limited side effects. To date, 3 medications have been approved by the US Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, and acamprosate. In addition to these approved medications, researchers have identified new therapeutic targets and, as a result, a number of alternative medications are now being evaluated for treatment of AUD in human studies. Although not approved by the FDA for the treatment of AUD, in some cases, these alternative medications are being used off-label by clinicians for this purpose. These potential medications are reviewed here. They include nalmefene, varenicline, gabapentin, topiramate, zonisamide, baclofen, ondansetron, levetiracetam, quetiapine, aripiprazole, and serotonin reuptake inhibitors. The effectiveness of these medications has been mixed—some show good efficacy with side effects that are mild to moderate in intensity; others have mixed or promising results but are awaiting findings from ongoing studies; and still others show poor efficacy, despite promising preliminary results. Medications development remains a high priority. Key initiatives for the National Institute on Alcohol Abuse and Alcoholism (NIAAA) include supporting the discovery and development of more effective and safer medications, advancing the field of personalized medicine, and forging public and private partnerships to investigate new and more effective compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340 · cited 4×
“Mason et al.(31) recently completed a 12-week trial of gabapentin (titrated to 900 and 1800 mg/day) with 150 alcohol-dependent patients.”
BackgroundInfluentialHeterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330
Self-citationLitten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 1×
“The most compelling evidence is from a recent multisite RCT of varenicline (2 mg/day) in 200 alcohol-dependent patients, approximately 40% of whom were smokers.(26) Compared with placebo, varenicline significantly reduced the primary outcome—percentage of heavy drinking days—by approximately 22% (37.”
BackgroundSelf-citationA double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal
Myrick, H., Malcolm, R., Randall, P. K., Boyle, E., Anton, R. F., Becker, H. C., & Randall, C. L. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00986.x · Cited by 201
Furieri, F. A., & Nakamura-Palacios, E. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1108 · Cited by 144
Mason, B. J., Light, J. M., Williams, L. D., & Drobes, D. J. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00133.x · Cited by 115 · cited 1×
“Gabapentin has been shown to reduce the unpleasant symptoms of withdrawal that may lead to a relapse to drinking,(29) including helping to alleviate insomnia and craving.(30) Mason et al.”
BackgroundKampman, K. M., Pettinati, H. M., Lynch, K. G., Spratt, K., Wierzbicki, M. R., & O’Brien, C. P. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.05.026 · Cited by 115 · cited 20×
“Finally, preliminary studies suggest that topiramate also may be effective in treating patients with comorbid disorders, such as AUD and posttraumatic stress disorder,45 and for treating patients addicted to cocaine with or without AUD.46,47 Topiramate has gained acceptance with clinicians, especially those working wi…”
BackgroundInfluentialBrown, E. S., Davila, D., Nakamura, A., Carmody, T. J., Rush, A. J., Lo, A., Holmes, T., Adinoff, B., Caetano, R., Swann, A. C., et al. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12445 · Cited by 50
Cited by
Anton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186
A Bayesian meta-analysis of topiramate’s effectiveness for individuals with alcohol use disorder
Fluyau, D., Kailasam, V. K., & Pierre, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221149643 · Cited by 20
“…gabapentin, nalmefene, topiramate (TPM), zonisamide, baclofen, ondansetron, levetiracetam, quetiapine, and aripiprazole (Fairbanks et al., 2020; Litten et al., 2016; Sarangi et al., 2022) seldom used are not widely approved for alcohol relapse prevention, except for nalmefene and baclofen in…”
BackgroundPharmacotherapy for alcohol use disorder.
Holt, S. R., & Tobin, D. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.008 · Cited by 17
Chompookham, P., Rukngan, W., Nilaban, S., Suwanmajo, S., Yoosom, P., & Kalayasiri, R. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.002 · Cited by 14
Metadata
- Authors
- Litten, R. Z., Wilford, B. B., Falk, D. E., Ryan, M. L., & Fertig, J. B.
- Venue
- Substance Abuse
- Publisher
- SAGE Publications
- Published
- 2016-04
- Volume
- 37
- Issue
- 2
- Pages
- 286-298
- ISSN
- 0889-7077 (ISSN-L)
- 1547-0164
- OpenAlex
- W2289934799
- Cited by
- 94
- References
- 10
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Medications for the Treatment of Alcohol use Disorder: An Evaluation of Clinical Efficacy and Safety. https://app.cochat.ai/papers/10.1080/08897077.2015.1133472
- The paper
- Litten, R. Z., Wilford, B. B., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016). Potential Medications for the Treatment of Alcohol use Disorder: An Evaluation of Clinical Efficacy and Safety. Substance Abuse. https://doi.org/10.1080/08897077.2015.1133472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.